Nektar Therapeutics

NKTR 
(NASDAQ) 
 
$ 40.26
Updated 13:03:18
Change % 0.00% Stock price unchanged
Change 0.00 Stock price unchanged
Volume 236
High $ 42.86
Low $ 40.22
Open $ 42.86
ISIN
Prev close $ 43.03
# of shares 173.09M
Market cap 6,968.41M USD
Intraday

Market closed
Nektar Therapeutics
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  40.26 -3.4% Stock price decreasing -10.1% Stock price decreasing 7.8% Stock price increasing -36.2% Stock price decreasing -54.4% Stock price decreasing
Powered by TradingView

News about Nektar Therapeutics

  • English
  • Regulatory news
15 Feb
 
31 Dec
 
31 Dec
 
29 Dec
 
28 Dec
 
27 Dec
 
26 Dec
 
26 Dec
 
26 Dec
 
24 Dec
 

Company profile

Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, chronic pain, hemophilia, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop NKTR-214, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 February 2019 13:26:43
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190215.1 - EUROWEB6 - 2019-02-22 14:26:43 - 2019-02-22 13:26:43 - 1000 - Website: OKAY